Related Experiment Videos

Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells

C T Yang1, L You, C C Yeh

  • 1Thoracic Oncology Laboratory, University of California, San Francisco Cancer Center, CA 94115, USA.

Abstract

Insights

Gene therapy using p14(ARF) shows promise for mesothelioma treatment. Introducing p14(ARF) via an adenoviral vector inhibits mesothelioma cell growth and induces cell death, highlighting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Mesothelioma often involves homozygous deletion of the INK4a/ARF locus, leading to p14(ARF) loss and p53 inactivation.
  • p14(ARF) protein normally promotes p53 activity by degrading MDM2, preventing MDM2-mediated p53 inhibition.

Purpose of the Study:

  • To evaluate the biological and therapeutic potential of p14(ARF) expression in mesothelioma cells.
  • To investigate the role of p14(ARF) in regulating cell cycle and apoptosis in mesothelioma.

Main Methods:

  • Constructed Adp14, an adenoviral vector carrying human p14(ARF) cDNA.
  • Transfected human mesothelioma cell lines (H28, H513, H2052, MSTO-211H) with Adp14.
  • Assessed cell growth, cell cycle progression, apoptosis, and cytotoxicity in response to Adp14 and control vectors.

Main Results:

  • Adp14 transfection led to overexpression of p14(ARF), increased p53 and p21(WAF) protein levels, and retinoblastoma protein dephosphorylation.
  • Mesothelioma cell growth was significantly inhibited by Adp14, inducing G1-phase cell cycle arrest and apoptotic cell death.
  • Adp14-mediated cytotoxicity was significantly greater in p53-proficient colon cancer cells than in p53-null cells, indicating functional p53 is critical.

Conclusions:

  • p14(ARF) overexpression in mesothelioma cells induces G1-phase arrest and apoptosis.
  • Gene therapy with Adp14 represents a potential therapeutic strategy for mesothelioma treatment.

Related Concept Videos